These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18379461)

  • 21. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 22. Milnacipran: new preparation. Tricyclics remain first-line antidepressants.
    Prescrire Int; 1998 Apr; 7(34):51-3. PubMed ID: 10183385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia.
    Jensen KB; Petzke F; Carville S; Choy E; Fransson P; Gracely RH; Vitton O; Marcus H; Williams SC; Ingvar M; Kosek E
    J Pain; 2014 Dec; 15(12):1328-37. PubMed ID: 25283470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Milnacipran for the treatment of chronic pain.
    Kamata M; Naito S; Takahashi H; Higuchi H
    Hum Psychopharmacol; 2003 Oct; 18(7):575-6. PubMed ID: 14533142
    [No Abstract]   [Full Text] [Related]  

  • 26. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
    Kito S; Nakajima T; Koga Y
    Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release.
    Nagayasu K; Kitaichi M; Nishitani N; Asaoka N; Shirakawa H; Nakagawa T; Kaneko S
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2295-306. PubMed ID: 23920436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
    Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
    Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
    Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
    Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
    Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB
    Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
    Leo RJ; Brooks VL
    Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
    Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T
    Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 35. alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
    Massé F; Hascoët M; Bourin M
    Behav Brain Res; 2005 Oct; 164(1):17-28. PubMed ID: 16081166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fluvoxamine, amitriptyline and transcranial electrostimulation of the brain in the treatment of chronic daily headache].
    Tarasova SV; Amelin AV; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):43-6. PubMed ID: 18577934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Milnacipran: beyond a role of antidepressant.
    Pae CU; Marks DM; Shah M; Han C; Ham BJ; Patkar AA; Masand PS
    Clin Neuropharmacol; 2009; 32(6):355-63. PubMed ID: 19620845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Japanese experience with dual-action antidepressants.
    Tajima O
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-42. PubMed ID: 12369609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.